Investment Rating - The report maintains a "Buy" rating for the company with a target price of 7.5 HKD, indicating that the current market price does not reflect the company's true value [1][4]. Core Insights - The company is expected to steadily reduce losses in 2024, with the neurointervention segment achieving its first annual profit. Revenue for 2024 is projected at 615 million RMB, a 40% year-over-year increase, with a gross margin of 70.5% [2][4]. - The cardiac valve segment is anticipated to generate 260 million RMB in revenue for 2024, also reflecting a 40% year-over-year growth, while the neurointervention segment is expected to reach 356 million RMB, marking a 39% increase [2][3]. - The report highlights that the market is closely monitoring the impact of centralized procurement, particularly in the neurointervention field, where risks are nearing resolution. In the cardiac valve sector, the slowdown in implant volume growth may not necessarily be negative due to potential price adjustments post-procurement [3][4]. Financial Performance Summary - Revenue projections for the company are as follows: 441 million RMB in 2023, 615 million RMB in 2024, 821 million RMB in 2025, 781 million RMB in 2026, and 1,024 million RMB in 2027, with year-over-year growth rates of 75.9%, 39.5%, 33.4%, -4.9%, and 31.2% respectively [5][12]. - The company is expected to narrow its net loss from 393 million RMB in 2023 to 228 million RMB in 2024, with further reductions anticipated in subsequent years [5][12]. - The report provides a detailed breakdown of revenue by segment, with cardiac valves and neurointervention contributing significantly to the overall growth [2][12]. Product Pipeline and Market Strategy - The company has separated three advanced products from its transcatheter valve business to prepare for independent financing and international expansion. These products are aimed at the European and American markets [4][14]. - The DCWire microguidewire is currently undergoing FDA registration and is expected to be the company's first original product to enter the international market [4][14]. - The report outlines the expected approval timelines for various products, including the TaurusNXT and TaurusTrio, which are anticipated to receive approval between late 2025 and mid-2026 [4][14].

Investment Rating - The report maintains a "Buy" rating for Nongfu Spring (9633.HK) with a target price of HKD 43.35, based on a current price of HKD 34.10 [1]. Core Insights - The report highlights that the bottled water segment is under short-term pressure, but recovery is expected as the peak season approaches. The company is also seeing growth in its tea beverage segment [1][8]. - The company reported a revenue of CNY 428.96 billion for 2024, a year-on-year increase of 0.54%, and a net profit of CNY 121.23 billion, up 0.36% year-on-year. The second half of 2024 saw a revenue decline of 6.7% [8][11]. - The report emphasizes the company's strong market position in bottled water and the ongoing high growth trend in its tea beverage business, supported by innovative product offerings and effective marketing strategies [8][9]. Financial Summary - **Revenue Forecast**: Expected revenues for 2025, 2026, and 2027 are CNY 493.18 billion, CNY 553.39 billion, and CNY 604.03 billion, respectively, with growth rates of 14.97%, 12.21%, and 9.15% [3][11]. - **Net Profit Forecast**: Projected net profits for the same years are CNY 141.25 billion, CNY 161.30 billion, and CNY 179.16 billion, with growth rates of 16.51%, 14.19%, and 11.07% [3][11]. - **Earnings Per Share (EPS)**: Expected EPS for 2025, 2026, and 2027 are CNY 1.26, CNY 1.43, and CNY 1.59, respectively [3][11]. - **Return on Equity (ROE)**: The ROE is projected to be 37.23% in 2025, 36.34% in 2026, and 34.75% in 2027 [3][11]. - **Price-to-Earnings (PE) Ratio**: The PE ratio is expected to decrease from 31.63 in 2024 to 21.41 in 2027 [3][11]. Business Segment Performance - **Bottled Water**: Revenue for 2024 was CNY 159.52 billion, down 21.3% year-on-year. The volume is expected to recover with a projected growth of 18% in 2025 [11][12]. - **Tea Beverages**: Revenue increased by 32.3% to CNY 167.45 billion in 2024, with continued strong growth expected [11][12]. - **Functional Beverages**: Revenue for 2024 was CNY 40.85 billion, with a growth forecast of 15.6% for 2025 [11][12]. - **Juice Beverages**: Revenue was CNY 11.82 billion in 2024, with a decline expected in the coming years [11][12]. Market Position and Strategy - The report notes that the company is well-positioned in the bottled water market and is expected to recover market share as the impact of recent controversies diminishes. The tea beverage segment continues to thrive, particularly in the no-sugar category [8][9][10]. - The company is focusing on product innovation and expanding its product matrix to align with health trends, which is expected to support long-term growth [8][9].

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Insights - The company reported a 2024 revenue of 5.54 billion yuan, representing a year-on-year growth of 57.2% - The net profit attributable to shareholders was 2.06 billion yuan, up 42.1% year-on-year, while the adjusted net profit reached 2.15 billion yuan, increasing by 46.5% [3][4]. Revenue Performance - The professional skincare products generated revenue of 5.52 billion yuan, a year-on-year increase of 57.4% - The efficacy skincare products accounted for 4.30 billion yuan in revenue, growing by 62.5% and representing 77.7% of total revenue, an increase of 2.6 percentage points - Medical dressings generated 1.22 billion yuan, up 41.5%, but its revenue share decreased by 2.4 percentage points [4]. Brand Performance - The company's flagship brand, 可复美, achieved revenue of 4.54 billion yuan, a 62.9% increase, making up 82.0% of total revenue, an increase of 2.9 percentage points - The 可丽金 brand generated 840 million yuan, growing by 36.3%, but its revenue share decreased by 2.3 percentage points [4]. Product and Channel Growth - The 可复美胶原棒 continued to see rapid growth, and new products received positive market feedback - During the "Double Eleven" sales event, 可复美's online GMV increased by over 80%, while 可丽金's online GMV surged by 150% [5][6]. - The DTC online sales channel generated 3.59 billion yuan, up 66.5%, while e-commerce platform sales reached 380 million yuan, growing by 112.5% [6]. Strategic Direction - The company is focused on brand building, channel expansion, and regulatory approval to ensure sustainable growth - New product launches and the opening of flagship stores are part of the strategy to enhance brand influence and expand online sales [7][8]. Financial Forecast - The company maintains its revenue and net profit forecasts for 2025, with an upward revision for 2026 net profit to 3.86 billion yuan, reflecting a 3% increase - New forecasts for 2027 are set at 12.75 billion yuan in revenue and 4.94 billion yuan in net profit [8][9].

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 19.00, indicating a potential upside of 26% from the current price of HKD 15.10 [1][9]. Core Insights - The company achieved a revenue of RMB 410.7 billion in 2024, a slight decrease of 0.8% year-over-year (YOY), while the net profit attributable to shareholders was RMB 27.7 billion, reflecting a growth of 16.1% YOY [9]. - The pharmaceutical segment, which constitutes 70.7% of the product mix, saw a revenue decline of 4.3% due to a drop in sales of COVID-related and anti-infection drugs, but innovative oncology and immunomodulatory products showed a growth of 6% [9]. - The company plans to distribute a cash dividend of RMB 3.20 per 10 shares, resulting in a dividend yield of approximately 2.3% for H shares [9]. - The company has a robust pipeline with over 80 projects in development, including innovative drugs and biosimilars, which are expected to drive future growth [9]. Summary by Sections Company Overview - The company operates in the pharmaceutical and biotechnology industry, with a market capitalization of HKD 83.34 billion and a share price-to-book ratio of 0.79 [2]. Financial Performance - In 2024, the company reported a net profit of RMB 27.7 billion, with a significant increase in operating cash flow to RMB 33.8 billion, up 31% YOY [9]. - The gross margin for the year was 48.0%, a slight increase of 0.2 percentage points, while the expense ratio decreased by 3.8 percentage points to 43.1% [9]. Future Projections - The company is expected to achieve net profits of RMB 33 billion, RMB 39 billion, and RMB 46 billion for the years 2025, 2026, and 2027, respectively, with YOY growth rates of 20.5%, 17.6%, and 17.3% [11]. - The earnings per share (EPS) are projected to be RMB 1.3, RMB 1.5, and RMB 1.7 for the same years, corresponding to H share price-to-earnings ratios of 11X, 10X, and 8X, indicating undervaluation [11].

Investment Rating - The report maintains a "Buy" rating for the company [2][6][18] Core Views - The company's gross margin has rebounded from its lowest point, and it is actively acquiring land in core cities, with nearly 80% of new land reserves acquired since 2022 [6][5] - The company reported a 2024 revenue of HKD 142.99 billion, a year-on-year increase of 6.4%, with property development contributing 97% of total revenue [6][5] - The company has a strong financial position, maintaining green status on the three red lines, with a financing cost that has reached a new low [6][5] Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: HKD 134.43 billion - 2024: HKD 142.99 billion - 2025E: HKD 149.85 billion - 2026E: HKD 157.19 billion - 2027E: HKD 172.28 billion [5][7] - The net profit attributable to the parent company is forecasted as: - 2023: HKD 5.04 billion - 2024: HKD 4.80 billion - 2025E: HKD 5.06 billion - 2026E: HKD 5.33 billion - 2027E: HKD 5.88 billion [5][7] - The company’s earnings per share (EPS) are projected to be: - 2023: HKD 2.36 - 2024: HKD 2.21 - 2025E: HKD 2.33 - 2026E: HKD 2.45 - 2027E: HKD 2.71 [5][7] Sales and Land Acquisition - The company’s total sales for 2024 were HKD 133.5 billion, a decrease of 29.3% year-on-year, with a sales return rate of 102% [6][5] - The land acquisition amount for 2024 was HKD 55.6 billion, down 52% year-on-year, with a land acquisition to sales ratio of 42% [6][5] - The company’s land reserves as of the end of 2024 amounted to 12.43 million square meters, with a sellable value of HKD 221 billion [6][5] Dividend and Shareholder Returns - The company declared a dividend of HKD 1.2 per share for 2024, maintaining a high dividend payout ratio of 52% and a dividend yield of 7.2% [6][5]

Investment Rating - The investment rating for the company is "Outperform the Market" [6][4][13] Core Insights - The company is expected to achieve a revenue of 55.39 billion with a year-on-year growth of 57.2% in 2024, and an adjusted net profit of 21.52 billion, reflecting a year-on-year increase of 46.5% [1][8] - The company has provided guidance for 2025, anticipating a revenue growth rate of 25-28% and a net profit of 25-25.5 billion, which represents a year-on-year increase of 21-24% [1][8] - The company continues to strengthen its market position in the collagen protein sector, supported by a robust product matrix and ongoing new product launches [4][13] Financial Performance - In 2024, the company achieved a gross profit margin of 82.1% and a net profit margin of 37.2%, with both margins showing a decline compared to the previous year [3][11] - The company’s revenue from its main brand, 可复美, reached 45.42 billion, marking a year-on-year increase of 62.9%, contributing to 82% of total revenue [2][9] - The company’s online sales channels have shown significant growth, with direct-to-consumer (DTC) sales increasing by 66.5% and e-commerce sales by 112.5% [2][9] Revenue Breakdown - The revenue from functional skincare products was 43.02 billion, reflecting a year-on-year growth of 62.5%, while medical dressings generated 12.18 billion, up 41.5% year-on-year [2][9] - The company has expanded its distribution channels, achieving revenue from DTC, e-commerce, offline, and distribution of 35.87 billion, 3.77 billion, 1.70 billion, and 14.05 billion respectively, with all channels showing positive growth [2][9] Future Projections - The company has slightly adjusted its net profit projections for 2025-2027, now estimating 25.49 billion, 30.92 billion, and 36.73 billion respectively, with corresponding price-to-earnings (PE) ratios of 26, 21, and 18 [4][13] - The company is expected to maintain its competitive edge in product quality and market presence despite rising costs associated with online platforms and increased marketing expenditures for new products [4][13]

Investment Rating - The report maintains a "Buy" rating for the company [4][17]. Core Views - The company's performance in 2024 was impacted by unfavorable wind conditions, leading to a decline in net profit and earnings per share [7]. - Despite the short-term challenges in the renewable energy sector, the long-term growth potential remains strong due to increased installed capacity [7]. - The company has a high dividend payout ratio, enhancing its investment appeal despite a decline in earnings [7]. Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: 20,282 million RMB - 2024: 21,372 million RMB (5% growth) - 2025E: 25,958 million RMB (22% growth) - 2026E: 28,108 million RMB (8% growth) - 2027E: 31,040 million RMB (10% growth) [3][8] - Net profit forecasts indicate a decline in 2024 to 1,672 million RMB, followed by a recovery to 2,803 million RMB in 2025 and 3,498 million RMB in 2027 [3][8]. - Earnings per share are projected to be 0.40 RMB in 2024, increasing to 0.67 RMB in 2025 and 0.83 RMB in 2027 [3][8]. - The company's return on equity is expected to improve from 7.71% in 2024 to 22.1% in 2027 [3]. Market Data - As of March 27, 2025, the company's closing price was 3.66 HKD, with a market capitalization of 153.93 billion HKD [4]. - The stock has a price-to-earnings ratio of 6.0 for 2025, decreasing to 4.8 by 2027 [3][4]. - The dividend per share for 2024 is set at 0.21 RMB, resulting in a dividend yield of 6.1% [7].

Investment Rating - The report maintains a "Buy" rating for China Oriental Education [2][8] Core Views - The company reported a revenue of RMB 4.12 billion for 2024, a year-on-year increase of 3.5%, and an adjusted net profit of RMB 525 million, up 86.6% year-on-year, driven by effective cost and expense control [5][6] - The company announced a year-end dividend of HKD 0.22 per share, corresponding to a payout ratio of 85%, with a dividend yield of approximately 5% [5] - The report anticipates continued growth in training numbers through the introduction of short-term courses and expansion in the beauty industry training sector [7][8] Financial Performance - Revenue for 2024 is projected at RMB 4.12 billion, with a year-on-year growth rate of 3.46% [9] - Adjusted net profit for 2024 is expected to be RMB 525 million, reflecting a significant year-on-year increase of 86.59% [9] - The company’s gross profit for 2024 is RMB 2.115 billion, with a gross margin of 51.4%, an increase of 3.4 percentage points year-on-year [6][11] Operational Efficiency - The company has effectively controlled costs, resulting in a net profit margin of 12.5%, an increase of 5.6 percentage points year-on-year [6] - Marketing expenses decreased by 6.1% year-on-year to RMB 970 million, with a sales expense ratio of 23.7%, down 2.4 percentage points [6] - The utilization rate of campuses improved from 72.2% in 2023 to 73.1% in 2024, contributing to economies of scale [6] Market Expansion - The company launched short-term courses targeting high school graduates, resulting in a 66.2% year-on-year increase in training numbers for these programs in the second half of 2024 [7] - The beauty industry training sector saw a 70.9% year-on-year increase in average training numbers, indicating strong demand recovery [7] - Five out of seven regional centers have been completed, enhancing the company's ability to offer higher-level vocational training [8] Profit Forecast - The adjusted net profit forecasts for 2025, 2026, and 2027 are RMB 617 million, RMB 732 million, and RMB 860 million respectively, with corresponding P/E ratios of 13.9, 11.7, and 10.0 [9][11]

2025 年 3 月 28 日 公司研究 深化"内生+外延"双轮驱动，"双美+双保健"业务模式焕发光彩 ——美丽田园医疗健康（2373.HK）2024 年年报点评 买入（维持） 当前价：18.10 港元 作者 分析师：姜浩 执业证书编号：S0930522010001 021-52523680 jianghao@ebscn.com 联系人：吴子倩 wuziqian@ebscn.com 市场数据 | 总股本(亿股) | 2.36 | | --- | --- | | 总市值(亿港元)： | 42.68 | | 一年最低/最高(港元)： | 13.03/19.88 | | 近 3 月换手率： | 11.66% | 股价相对走势 | 收益表现 | | | | | --- | --- | --- | --- | | % | 1M | 3M | 1Y | | 相对 | 4.60 | -12.75 | 24.88 | | 绝对 | 2.77 | 7.61 | 25.30- | | 资料来源：Wind | | | - | 相关研报 中国双美模式龙头企业，稳扎稳打开拓美与 健康大市场——美丽田园医疗健康 （2373.HK）首次覆 ...

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 15.50 [8][9]. Core Views - The company's 2024 EPS is projected to be RMB 1.45, representing a 31% year-on-year increase, driven mainly by improved equity investments [1]. - The overall combined ratio (COR) for the company is expected to be 98.8%, reflecting a 1 percentage point increase year-on-year, primarily due to natural disaster impacts [1]. - The company is anticipated to maintain steady growth in its business, particularly in the auto insurance sector, which is expected to grow at a rate of 4.5% in 2024 [2]. Summary by Sections Auto Insurance Performance - The auto insurance COR for 2024 is projected at 96.8%, remaining stable compared to 96.9% in 2023. The loss ratio has increased by 2.2 percentage points to 72.6%, offset by a decrease in expense ratio [2]. - The auto insurance business revenue is expected to grow by 4.5% year-on-year, indicating a stable market outlook [2]. Non-Auto Insurance Performance - The non-auto insurance COR is estimated to rise by 2.8 percentage points to 101.9% in 2024, indicating underwriting losses. The loss ratio has increased by 2.7 percentage points, while the expense ratio remains stable [3]. - Revenue from property insurance is expected to grow by 4.7%, with a COR of 113.4%. Agricultural insurance revenue is projected to increase by 4.9%, with a COR of 99.7% [3]. Capital Returns - The return on equity (ROE) for the company is expected to rise by 2 percentage points to 13.1% in 2024, supported by favorable investment conditions. The total investment return rate is projected to increase to 5.5% [4]. - The company plans to distribute a dividend of RMB 0.54 per share for 2024, up from RMB 0.49 in 2023, with a payout ratio of 37% [4]. Earnings Forecast and Valuation - The EPS forecasts for 2025, 2026, and 2027 have been raised to RMB 1.62, RMB 1.69, and RMB 1.82 respectively, reflecting adjustments of 12.7% and 8.0% for the first two years [5]. - The target price based on DCF valuation has been increased to HKD 15.50 from HKD 13.60, maintaining the "Buy" rating [5].